PECAM1 and depressive symptom measurement: Increased serum levels of soluble ICAM-1 and PECAM-1 are observed in a number of neuropsychiatric disorders (i.e., depression, bipolar disorder, dementia, and progressive vascular cognitive disorders) [6,18].